Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer.

Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, Vodicka P.

Mutagenesis. 2012 Mar;27(2):211-8. doi: 10.1093/mutage/ger067. Review.


Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?

Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, Chang-Claude J.

Pharmacogenet Genomics. 2007 Aug;17(8):639-45.


p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.

Bouzourene H, Gervaz P, Cerottini JP, Benhattar J, Chaubert P, Saraga E, Pampallona S, Bosman FT, Givel JC.

Eur J Cancer. 2000 May;36(8):1008-15.


Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.

Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N.

Ann Oncol. 2005 May;16 Suppl 4:iv44-49. Review.


Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, Janschek E, Kappel S, Lung M, Leung CS, Ko JM, Yuen S, Ho J, Leung SY, Crapez E, Duffour J, Ychou M, Leahy DT, O'Donoghue DP, Agnese V, Cascio S, Di Fede G, Chieco-Bianchi L, Bertorelle R, Belluco C, Giaretti W, Castagnola P, Ricevuto E, Ficorella C, Bosari S, Arizzi CD, Miyaki M, Onda M, Kampman E, Diergaarde B, Royds J, Lothe RA, Diep CB, Meling GI, Ostrowski J, Trzeciak L, Guzinska-Ustymowicz K, Zalewski B, Capellá GM, Moreno V, Peinado MA, Lönnroth C, Lundholm K, Sun XF, Jansson A, Bouzourene H, Hsieh LL, Tang R, Smith DR, Allen-Mersh TG, Khan ZA, Shorthouse AJ, Silverman ML, Kato S, Ishioka C; TP53-CRC Collaborative Group.

Ann Oncol. 2006 May;17(5):842-7. Epub 2006 Mar 8.


TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population.

Sameer AS, Shah ZA, Syeed N, Banday MZ, Bashir SM, Bhat BA, Siddiqi MA.

Genet Mol Res. 2010 Apr 13;9(2):651-60. doi: 10.4238/vol9-2gmr751.


Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.

Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D.

Hum Mutat. 2006 Jan;27(1):110-7.


Different mutation profiles associated to P53 accumulation in colorectal cancer.

López I, P Oliveira L, Tucci P, Alvarez-Valín F, A Coudry R, Marín M.

Gene. 2012 May 10;499(1):81-7. doi: 10.1016/j.gene.2012.02.011. Epub 2012 Feb 21.


TP53 codon 72 and intron 3 polymorphisms and mutational status in gastric cancer: an association with tumor onset and prognosis.

Neves Filho EH, Cordeiro DE, Vieira AP, Rabenhorst SH.

Pathobiology. 2012;79(6):323-8. doi: 10.1159/000338436. Epub 2012 Jun 9.


TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis.

Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S.

Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1840-7. doi: 10.1158/1055-9965.EPI-10-0156. Review.


The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.

Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N; TP53-CRC Collaborative Study Group.

J Clin Oncol. 2005 Oct 20;23(30):7518-28. Epub 2005 Sep 19. Review.


Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.

Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W, Jassem J.

Lung Cancer. 2006 Apr;52(1):9-14. Epub 2006 Feb 24.


Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer.

Hao XD, Yang Y, Song X, Zhao XK, Wang LD, He JD, Kong QP, Tang NL, Zhang YP.

Oncol Rep. 2013 Jan;29(1):226-36. doi: 10.3892/or.2012.2098. Epub 2012 Oct 22.


[Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer].

Wang AZ, Zhu ZZ, Cong WM.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Apr;25(2):168-71. Chinese.


DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications.

Klumb CE, Furtado DR, de Resende LM, Carriço MK, Coelho AM, de Meis E, Maia RC, Rumjanek FD.

Eur J Haematol. 2003 Aug;71(2):81-90.


Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.

Lind H, Ekstrøm PO, Ryberg D, Skaug V, Andreassen T, Stangeland L, Haugen A, Zienolddiny S.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2077-81.


[TP53 mutations and molecular epidemiology].

Otsuka K, Ishioka C.

Gan To Kagaku Ryoho. 2007 May;34(5):683-9. Review. Japanese.


P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.

de Jong KP, Gouw AS, Peeters PM, Bulthuis M, Menkema L, Porte RJ, Slooff MJ, van Goor H, van den Berg A.

Clin Cancer Res. 2005 Jun 1;11(11):4067-73.


Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.

Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, Tomasino RM, Colucci G, Gebbia N, Russo A; Gruppo Oncologico dell'Italia Meridionale (GOIM).

Ann Oncol. 2005 May;16 Suppl 4:iv50-55.


[TP53 gene polymorphisms and colorectal cancer risk in Chinese population].

Jia HR, He XL, Zhu ZZ, Jin XX, Wang AZ, Huang HY, Zhu J, Yu GB, Zhu GS.

Zhonghua Yi Xue Za Zhi. 2007 Jun 5;87(21):1448-51. Chinese.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk